The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prognostic markers in triple‐negative breast cancer
Abstract
BACKGROUND.: Triple‐negative breast cancer (estrogen receptor‐negative, progesterone receptor‐negative, and HER2‐negative) is a high risk breast cancer that lacks the benefit of specific therapy that targets these proteins. METHODS.: In this study, the authors examined a large and well characterized series of invasive breast carcinoma (n = 1944) with a long‐term clinical follow‐up (median, 56 months) by using tissue microarray. The series were also stained with concurrent immunohistochemical prognostic panels (estrogen receptor, progesterone receptor, HER‐2, androgen receptor, epidermal growth factor receptor (EGFR), P‐cadherin, E‐cadherin, and basal (CK5/6, CK14), and p53), to characterize this specific subgroup of breast cancer and to identify prognostic markers that can identify tumors with more aggressive behavior. RESULTS.: Of informative cases, 16.3% were of the triple‐negative phenotype. The majority of these tumors were grade 3, ductal/no‐specific‐type carcinomas. There were positive associations with larger size, pushing margins, poorer Nottingham Prognostic Index, development of recurrence and distant metastasis, and poorer outcome. In addition, associations were found with loss of expression of androgen receptor and E‐cadherin, and positive expression of basal cytokeratins (basal phenotype), P‐cadherin, p53, and EGFR. In all tumors, tumor size, lymph node stage, and androgen receptor were the most useful prognostic markers. In the lymph node‐positive subgroup, both size and androgen receptor retained their prognostic significance. However, in the lymph node‐negative tumors, basal phenotype was the sole prognostic marker identified in this subgroup. Other parameters including age, histological grade, tumor size, vascular invasion or other biomarkers included in the current study were not significant. CONCLUSIONS.: The authors concluded that assessment of androgen receptor and basal phenotype, in addition to the established pathologic variables, mainly lymph node status and tumor size, can be used to select high‐risk and low‐risk patients at the time of primary surgery and can provide valuable information on treatment options in these triple‐negative tumors. Cancer 2007. © 2006 American Cancer Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Self-citationRepeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Carter, C. L., Allen, C., & Henson, D. E. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h · Cited by 2,288
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. E., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,070
Self-citationGusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Validation of Tissue Microarray Technology in Breast Carcinoma
Camp, R. L., Charette, L. A., & Rimm, D. L. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780204 · Cited by 799
Mattie, M. D., Benz, C. C., Bowers, J., Sensinger, K., Wong, L., Scott, G. K., Fedele, V., Ginzinger, D. G., Getts, R. C., & Haqq, C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-24 · Cited by 787
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Self-citationExpression of luminal and basal cytokeratins in human breast carcinoma
Abd El‐Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R., Robertson, J. F., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594
Self-citationvan de Rijn, M., Perou, C. M., Tibshirani, R., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Köchli, O. R., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64476-8 · Cited by 560
Rakha, E., Putti, T., Abd El‐Rehim, D., Paish, C., Green, A., Powe, D., Lee, A., Robertson, J., & Ellis, I. (2006) · The Journal of Pathology · doi:10.1002/path.1916 · Cited by 311
Self-citationSteroid Hormone Receptor Status of Mouse Mammary Stem Cells
Asselin-Labat, M.-L., Shackleton, M., Stingl, J., Vaillant, F., Forrest, N. C., Eaves, C. J., Visvader, J. E., & Lindeman, G. J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj267 · Cited by 293
Towards a novel classification of human malignancies based on gene expression patterns
Alizadeh, A. A., Ross, D. T., Perou, C. M., & van de Rijn, M. (2001) · The Journal of Pathology · doi:10.1002/path.889 · Cited by 280
Abd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J. A., Rampaul, R. S., Blamey, R. W., Robertson, J. F. R., Nicholson, R. I., & Ellis, I. O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602184 · Cited by 256
Self-citationBryan, B. B., Schnitt, S. J., & Collins, L. C. (2006) · Modern Pathology · doi:10.1038/modpathol.3800570 · Cited by 217
Agoff, M., Swanson, M., Linden, M., Hawes, P., & Lawton, M. (2003) · American Journal of Clinical Pathology · doi:10.1309/42f0-0d0d-jd0j-5edt · Cited by 211
Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis
Hayes, D. F., Isaacs, C., & Stearns, V. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014778713034 · Cited by 207
Agoff, S. N., Swanson, P. E., Linden, H., Hawes, S. E., & Lawton, T. J. (2003) · American Journal of Clinical Pathology · doi:10.1309/42f00d0djd0j5edt · Cited by 206
Malzahn, K., Mitze, M., Thoenes, M., & Moll, R. (1998) · Virchows Archiv · doi:10.1007/s004280050226 · Cited by 174
Dysregulation of cellular signaling by HER2 in breast cancer
Zhou, B. P., & Hung, M.-C. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.006 · Cited by 149
Parl, F. F., Schmidt, B. P., Dupont, W. D., & Wagner, R. K. (1984) · Cancer · Cited by 146
Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers
Pichon, M., Broët, P., Magdelénat, H., Delarue, J., Spyratos, F., Basuyau, J., Saez, S., Rallet, A., Courriere, P. H., Millon, R., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.291 · Cited by 141
Lohrisch, C. A. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90103-4 · Cited by 113
Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer
Potemski, P., Kusińska, R., Watała, C. W., Płuciennik, E., Bednarek, A. K., & Kordek, R. (2005) · Oncology · doi:10.1159/000090986 · Cited by 102
E-cadherin as a prognostic indicator in primary breast cancer
Parker, C. A., Rampaul, R. S., Pinder, S. E., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2178 · Cited by 83
Predictive and prognostic markers for invasive breast cancer
Mori, I., Yang, Q., & Kakudo, K. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01335.x · Cited by 65
C-erb-B2 expression and response to treatment in metastatic breast cancer
Bezwoda, W. R. (2000) · Medical Oncology · doi:10.1007/bf02826212 · Cited by 15
Cited by
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Self-citationCheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Self-citationTriple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Metadata
- Authors
- Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-12-11
- Volume
- 109
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1989663680
- Cited by
- 1,283
- References
- 31
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.